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Abstract
Background: Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different
criteria and lack background information on the decision making process. User acceptance of rating systems could
be improved by providing a transparent decision path for each category.
Methods: We rated 200 randomly selected potential drug-drug interactions by a transparent decision model
developed by our team. The cases were generated from ward round observations and physicians’ queries from an
outpatient setting. We compared our ratings to those assigned by a senior clinical pharmacologist and by a
standard interaction database, and thus validated the model.
Results: The decision model rated consistently with the standard database and the pharmacologist in 94 and 156
cases, respectively. In two cases the model decision required correction. Following removal of systematic model
construction differences, the DM was fully consistent with other rating systems.
Conclusion: The decision model reproducibly rates interactions and elucidates systematic differences. We propose
to supply validated decision paths alongside the interaction rating to improve comprehensibility and to enable
physicians to interpret the ratings in a clinical context.
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Background
The management of adverse drug events (ADEs) is an
important issue in healthcare [1]. While some ADEs are
unpredictable (e.g. anaphylaxis), ADEs caused by drug-
drug interactions (DDI) are likely to be preventable [2].
Nevertheless, DDIs continue to present a major problem
in medical treatment. One Swiss study estimated that
17% of all ADEs occurring in hospitalized patients are
provoked by DDIs [3], while a Dutch study found that
28% of patients admitted to the hospital experienced at
least one DDI [4]. Clinical decision support software
(CDSS) has been used as a supportive measure to im-
prove medication safety [5,6]. The information provided
by CDSS focuses on management advice rather than
alerts, since more prevalent alerts may dominate less
common but equally dangerous ones [4].
In the past, DDIs were classified according to their po-
tential severity e.g. minor, moderate, or major. In 2001 a
new management-oriented approach to DDI classifica-
tion was advanced by Hansten and Horn [7]. More than
75% of majorly severe interactions are considered man-
ageable [8]; therefore this approach seems reasonable.
Recently, a separate group in our department developed
ZHIAS (Zurich Interaction System), an extension of the
clinical management approach, which is based on Oper-
ational Classification of Drug Interactions (ORCA)
[9,10]. Another management-oriented classification sys-
tem is based on types of adverse drug reactions [8]. Even
with multiple classifications being available, the assess-
ment of DDIs depends on both the experience and the
interpretation of the assessor as well as the sources of
information used in the assessment [11]. The discrepan-
cies between different DDI ratings are well-documented
[7,12-14]. No two DDI databases use the same set of cri-
teria to assign severity ratings [15]. For example, the
assigned interaction severity between alprazolam and
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digoxin ranges from “no interaction” to “major inter-
action”, depending on database [16-19]. It remains un-
clear whether these rating discrepancies arise from
inconsistent study results or from the use of different
DDI classification algorithms. One case report and one
study showed that plasma digoxin concentrations signifi-
cantly increase in the presence of alprazolam [20]. A
separate study involving healthy volunteers reported no
clinically relevant change in digoxin plasma concentra-
tions [21]. In the past 30 years, more than 15,000 papers
on DDIs have been published [7]. The problem we face
today is not the lack of information on DDIs or the type
of classification, but the incompatibility of DDI rating
systems. Alerts are often disregarded by physicians, if
background information on the decision layer and prac-
tical management recommendations are lacking [22,23].
In order to increase user acceptance, the DDI rating
must be consistent and comprehensible, and the deci-
sion model must be transparent [24].
To improve rating comprehensibility, we developed a
transparent decision model (DM) to rate drug interac-
tions. The model is based on previous research by van
Roon and colleagues [25]. The aim of our current re-
search is to validate the transparent decision model in
terms of reproducibility and identification of systematic
differences between DDI ratings.
Methods
Design of decision model
In designing the DM, we developed a list of binary ques-
tions which we considered would impact on the inter-
action rating. Similar questions were constructed
iteratively, and six sets of clinically relevant questions
were ultimately retained. The questions were evaluated
regarding their relevance to a robust and comprehen-
sible DDI rating system. The sequential order of the six
binary questions (see Figure 1) was permuted by a re-
view team consisting of one pharmacist, two clinical
pharmacologists and one physician, until consensus
regarding the rating outcome of the DM was achieved.
The six question sets are outlined as follows:
1. Apparent interaction (AIA) comprised two sub-
questions:
Only one “yes” answer is required to progress down
the decision path to the next question.
a)Has this interaction been described in the scientific
literature (e.g. credible clinical studies and credible
case reports)?
b) Can one postulate a plausible, hypothetical
mechanism of pathogenic interaction?
2. Serious adverse event (SAE) inquires into the clinical
severity of the interaction: Is there an increased risk
for the occurrence of an SAE within the normal
patient population?
3. Action (ACT) determines whether medical
intervention is necessary: Does the interaction
outcome necessitate medical intervention, other than
simple precautionary measures?
4. Surveillance (SUR) ascertains whether the
consequences of the interaction can be easily
monitored: Is the interaction risk difficult to assess in
an out-patient setting and within a short time-frame?
5. Alternative (ATE) questions whether a safer
alternative to either one of the drugs exists. It
comprises two sub-questions.
Both questions must be answered “yes” in order to
proceed to the final step of the decision model.
a) Does a suitable alternative exist (within the same
ATC category), which carries a lower potential for
interaction?
b) Are credible dose adjustment guidelines
unavailable?
6. Risk-benefit ratio (RBR): Does the risk outweigh the
potential benefit?
The DM presents 13 possible decision paths leading to
5 possible interaction ratings: DM: A (no action
required), DM: B (precautionary measures), DM: C (clin-
ical monitoring), DM: D (avoid) and DM: E (contraindi-
cated). For statistical analysis numbers 1 up to 5 were
assigned to the ratings. The ratings are defined to avoid
ambiguity and are based on clinical management. A rat-
ing of DM: A indicates that co-administration is safe,
based on currently available scientific data. When an
interaction is rated DM: B, precautionary monitoring for
unusual side effects is sufficient. DM: C signifies that, al-
though no alternative therapies are available, the likely
effect of the interaction is easily monitored. Necessary
medical action will be guided by the relevant pub-
lished medical guidelines. DM: D indicates that co-
administration should be avoided and only undertaken
when deemed imperative. DM: E states clearly that
the drugs must not be co-administered in any clinical
situation. The interaction ratings were standardized to
ensure consistency in rating outcomes by different
physicians/pharmacists. The DDI rating was designed
for integration into a network of additional decision
support systems, such as patient-specific risk factors
(e.g. old age, obesity, or renal insufficiency) or drug-
disease state contraindications, whereas the DM refers
to the low-risk normal population. A serious adverse
event is defined as a life-threatening or debilitating
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event, resulting in death, inpatient hospitalization or
prolongation of existing hospitalization, or persistent or
significant disability/incapacity. Risk/benefit defines the
balance between the effectiveness of a medicine and
the risk of harm as specified by the World Health
Organization Uppsala Monitoring Centre (WHO-UMC)
in Sweden.
Other ratings
One of our assessors, a clinical pharmacologist, classified
DDIs into five categories, namely: “no interaction”,
"minor", "moderate", "major" and "contraindicated",
based on her personal clinical experience and interpret-
ation of the available literature relating to drug interac-
tions. The Micromedex DrugDex (MMX) database
classifies DDIs as "unknown", "minor", "moderate",
"major" or "contraindicated". MMX also estimates the
quality of DDI documentation, rating it as either "excel-
lent", "good", "fair" or "unknown".
Validation of decision model
In our study we randomly selected 200 potential drug
interactions and compared the individual rating out-
comes generated by three different rating methods. Clin-
ical relevance of the drug interactions was assessed from
queries received at the Department of Clinical Pharmacol-
ogy and Toxicology at the University Hospital in Zurich,
raised by pharmacists and physicians in primary and sec-
ondary care and from ward rounds at the University
Hospital. In the first rating method, one pharmacist ap-
plied our DM to manually rate the 200 interactions. The
ratings were then reviewed and revised for plausibility by
a team comprising two clinical pharmacologists and one
physician. The second rating was performed by an inde-
pendent senior clinical pharmacologist who was blinded
with respect to the DM and who assigned each interaction
rating based on her clinical experience and knowledge.
The clinical pharmacologist was not permitted use of an
interaction database, but was allowed access to available
scientific sources such as PubMed database, Excerpta
Medica database (Embase), European Public Assessment
Reports (EPARs) and summary of product characteristics.
The same information sources were accessible to the
pharmacist. In the third rating method, a physician rated
the 200 interactions using the commercially available
MMX database [16].
Statistical methods
The concordance between all three ratings was deter-
mined using cross-tables, together with ordinary and
weighted Cohen’s Kappa coefficients. Cohen’s Kappa
measures the extent to which any two rating systems
agree by chance alone. It ranges from zero (agreement
no better than chance) to one (perfect agreement). In
the tables, values adjacent to the diagonal (ratings differ-
ing by a single category) are considered less serious than
deviations of two or more categories. Cohen’s Kappa
evaluates inter-rater agreement as follows: 0.01–0.2
Figure 1 Visualisation of proposed action-oriented decision model to rate drug-drug interactions. The six question sets relate to: AIA
(apparent interaction), SAE (serious adverse event), ACT (action), SUR (surveillance), ATE (alternative), RBR (risk-benefit ratio). Five possible ratings
are DM: A (no action required), DM: B (precautionary measures), DM: C (clinical monitoring), DM: D (avoid) and DM: E (contraindicated).
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slight agreement; 0.21–0.40 fair agreement; 0.41–0.60
moderate agreement; 0.61–0.80 substantial agreement
and 0.81–1 perfect agreement [26]. To identify systematic
differences between the rating systems, Bland–Altman
plots, which illustrate agreement limits, were constructed.
Identified systematic differences were reviewed indi-
vidually by the aforementioned review team and were
excluded from further analysis. The relative frequencies
and confidence intervals of the remaining disagree-
ments were determined by the Wilson method [27].
Results
The pharmacist, physician and the clinical pharmacolo-
gist independently assessed all cases of potential drug
interactions (n = 200). 62 of the interactions yielded no
information from MMX regarding possible DDIs. The
ratings evaluated by the pharmacist and the clinical
pharmacologist ranged from DM: B (precautionary mea-
sures) to DM: E (contraindicated).
Concordance
Agreement between the DM and the clinical pharma-
cologist was high, with a ordinary Kappa coefficient of
0.692 (95% CI [0.611, 0.744]) and weighted Kappa of
0.805 (95% CI [0.747, 0.863]). Agreement between the
DM and MMX was fair with a ordinary Kappa coeffi-
cient of 0.315 (95% CI [0.233, 0.397]) and weighted
Kappa of 0.363 (95% CI [0.276, 0.449]). The DM was
concordant with the clinical pharmacologist and with
MMX in 156 (78% (95% CI [72, 83])) and 94 cases (47%
(95% CI [40, 54])), respectively. Likewise the clinical
pharmacologist and MMX agreed in 89 (45% (95% CI
[38, 51])) of the 200 interaction cases. Tables 1 and 2
show the DDI cross-ratings between DM and clinical
pharmacologist and DM and MMX, respectively.
Divergence
We corrected the rating of the pharmacist in two cases,
where the DM was applied incorrectly. The application
error rate occurred in 1% of all 20 cases (95% CI [0, 3]).
The first error, in the assessment of roxithromycin and
simvastatin co-administration, was caused by incorrect
interpretation of the DM question. The pharmacist ap-
plied the serious adverse events (SAEs) question to the
“at-risk” population instead of to the “normal patient”
population. Therefore the rating of DM: D (avoid)
assigned to this interaction by the pharmacist, required
correction to DM: B (precautionary measures). No fur-
ther information about this rating was extracted from
MMX, so a third rating was unavailable for comparison.
The second error regarded the combination of atenolol
and bupropion. The pharmacist did not use all available
information to rate the interaction and in particular did
not consider that co-administration can induce blood
pressure changes, and thus may alter the effect of ateno-
lol. Therefore the rating of DM: A (no action required)
assigned to this interaction by the pharmacist, required
correction to DM: B (precautionary measures).
Systematic difference
Systematic differences between the ratings of DM and
MMX are displayed as a Bland–Altman plot in Figure 2.
The mean difference is 0.9 and perfect agreement (zero)
lies outside the confidence interval. The rankings dif-
fered by up to three classification categories. The limits
of agreement were [−1.6, 3.4], indicating that the DM
tends to rate a higher severity. Not shown are the sys-
tematic differences for clinical pharmacologist versus
MMX (mean difference: 0.8, limits of agreement [−1.5,
3.1]), and DM versus clinical pharmacologist (mean dif-
ference: 0.13, limits of agreement [−0.8, 1.05]).
Systematic-difference based disagreements in DM ver-
sus MMX and DM versus clinical pharmacologist
Table 1 Cross correlation of drug-drug interaction ratings
for clinically identified cases (n = 200) between the
proposed decision model (DM) and a clinical
pharmacologist
Clinical Pharmacologist
A B C D E Total
DM A 18 3 0 0 0 21
B 2 10 0 0 0 12
C 0 0 49 5 0 54
D 0 1 30 60 2 93
E 0 0 0 1 19 20
Total 20 14 79 66 21 200
Ratings are A (no action required), B (precautionary measures), C (clinical
monitoring), D (avoid) and E (contraindicated). Systematic differences between
ratings are highlighted.
Table 2 Cross correlation of drug-drug interaction ratings
for clinically identified cases (n = 200) between the
proposed decision model (DM) and Micromedex (MMX)
MMX
A B C D E Total
DM A 21 0 0 0 0 21
B 8 0 4 0 0 12
C 18 4 26 6 0 54
D 32 1 25 34 1 93
E 4 0 0 3 13 20
Total 83 5 55 43 14 200
Ratings are A (no action required), B (precautionary measures), C (clinical
monitoring), D (avoid) and E (contraindicated). The rating X from MMX has
been labeled E. Missing ratings from MMX have been labeled A. Systematic
differences between ratings are highlighted.
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assessments were excluded from further analysis. The
corresponding cells are highlighted in Tables 1 and 2.
Figure 3 shows the Bland–Altman plot of the remaining
data set for DM and MMX. The mean difference de-
creased to −0.02, statistically the same as perfect agree-
ment, while limits of agreement narrowed down to [−0.89,
0.85]. The rankings differed by at most one rating.
The remaining 14 (of the 200 ratings) disagreed be-
tween the DM and clinical pharmacologist for reasons
not explained by systematic differences (these non-
systematic discrepancies account for 7% (95% CI [4,11])
of all ratings). The remaining 19 non-systematic dis-
agreements between DM and MMX constitute 9.5%
(95%CI: [6,14]).
Figure 2 Bland-Altman plot of differences in ratings assigned to clinically identified drug-drug interactions (n = 200) by the proposed
decision model (DM) and Micromedex (MMX). Data includes those interactions for which MMX had no rating (n = 62) as highlighted in cells
(A,B),(A,C),(A,D) and (A,E) from Table 2.
Figure 3 Bland-Altman plot of differences in ratings assigned to clinically identified drug-drug interactions (n = 113) by the proposed
decision model (DM) and Micromedex (MMX). Data is based on 200 drug-drug interactions, but excludes those interactions for which MMX
had no rating (n = 62) and those ratings with systematic differences (n = 25) (highlighted cells in Table 2).
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Discussion
We evaluated a transparent decision model that repro-
ducibly rates drug interactions and identifies systematic
rating discrepancies. Altman [26] suggests that kappa is
the appropriate means of judging agreement or reprodu-
cibility between classification categories obtained by two
different rating methods and is supported by the higher
weighted Kappa values, which strengthened the ap-
proach in the present study. No systematic differences
showed up on the Bland–Altman plot of DM versus
MMX, following removal of the systematic differences.
Divergence in decision making remains an issue and re-
view of certain cases is unavoidable. The review time,
however, decreases as a result of the standardization.
When comparing two ratings, our visualization of the
decision path enables rapid comprehension of one side
of the differences [28], thus clarifying (at least partially)
the rating discrepancies. Such transparency improves the
clinical value of the interpretation of the rating [29,30].
To our knowledge, we publish the first visualized deci-
sion model that is comparable with other ratings. Previ-
ously published ratings, though based on expert group
decisions, are not guided by specified rules of an algo-
rithm. The output of the decision model, corrected for
systematic differences between rating systems, closely
resembles that of other ratings. To illustrate the system-
atic nature of these differences, we summarize the most
important ones (highlighted in the cross tables) below.
Systematic differences
If more than simple precautionary measures are required
in first line therapy, or if complex monitoring of a likely
side-effect is required, we assume that a suitable drug al-
ternative precludes co-administration, because the latter
disproportionately raises patient risk or health care
costs. This explains why DM rated 30 cases of higher se-
verity than the clinical pharmacologist (Table 1) and 25
cases of higher severity than MMX (Table 2).
Interactions requiring complex monitoring were rated
of higher severity by DM than either the clinical
pharmacologist (DM rated 18 of 30 cases more severely)
or MMX (DM rated 21 of 25 cases more severely). (i)
The clinical pharmacologist assigned a rating of C
(“moderate”) to the combination of citalopram and tra-
madol, whereas both DM and MMX recommended
avoiding this combination (ratings: DM: D and “major”,
respectively), since co-administration increases the risk
of serotonin toxicity. Monitoring for SAEs such as
hyperreflexia, CNS symptoms, myoclonus, sweating and
hyperthermia is imperative and is complex in an out-
patient setting. (ii) Risk of amiodarone and phenytoin
co-administration was rated C (“moderate”) by MMX
and C (“precautionary measures”) by the clinical
pharmacologist. The DM assigned a rating of D
(“avoid”), since amiodarone concentrations in plasma
may be reduced to as low as 30% in the presence of
phenytoin. This effect can occur several weeks into
phenytoin therapy, therefore amiodarone concentrations
must be monitored for several weeks to enable dose
adjustment. Furthermore, phenytoin toxicity can occur
and surveillance requires considerable effort. (iii) Co-
administration of duloxetine and amitriptyline increases
the risk of anticholinergic or serotonin syndrome and
may lead to elevated amitriptyline plasma concentra-
tions. Because of the complex clinical surveillance
required, this interaction was rated D by the DM,
whereas MMX assigned a C rating.
The inclusion of suitable treatment alternatives in the
decision process caused DM to rate an interaction more
severely than the clinical pharmacologist in 12 of 30
cases, and more severely than MMX in 4 of 25 cases. (i)
Co-administration of digoxin and alprazolam was rated
C by the clinical pharmacologist, since alprazolam inter-
feres with digoxin levels and therefore requires drug
concentration monitoring at the initiation and dis-
continuation of alprazolam therapy. The DM rated this
interaction as D, because a suitable alternative (lorazepam)
exists. (ii) MMX rated the combination of midazolam and
phenytoin as “moderate”. Although the co-presence of
phenytoin depresses midazolam levels, alternative ben-
zodiazepines are available which carry a lower potential
for interaction.
In one case, a rating discrepancy of two categories was
found (the drug combination was rated B by MMX and
D by DM). The drugs in question were fluconazole and
fluvastatin, for which co-administration increases the
risk of severe myopathy while an alternative to fluvasta-
tin exists.
Study limitations
This study focused solely on the decision making
process, and the positive contribution of the rating out-
put to medical therapy was not evaluated. Although
every attempt has been made to ensure that the categor-
ies are objective (i.e. they represent a consensus between
four clinical specialists in three different fields), they are
nonetheless subject to user interpretation and should
not be regarded as a “gold standard”, but as an approach
to standardize ratings with defined rules. We hope that
publication of this decision model will stimulate other
groups to test the models’ reproducibility. The feasibility
of the decision model to illustrate system differences has
been tested with a single database, MMX. In future, the
DM may elucidate systematic differences between other
rating discrepancies reported in the literature [11,13,14].
Concordance between the DM and expert assessment
has been validated by only one pharmacist from our
group.
Far et al. BMC Clinical Pharmacology 2012, 13:7 Page 6 of 8
http://www.biomedcentral.com/1472-6904/13/7
The agreement between DM and MMX was evaluated
as “fair”, which can be explained partly by systematic dif-
ferences in 25 cases, but which must also consider the
missing information from MMX in 62 cases. The omis-
sion of information in MMX regarding a specific drug
combination cannot be considered as the absence of a
DDI. Therefore our database distinguishes between
missing information and a safe combination (DM: A).
No information was yielded by MMX for the following
complications of drug co-administration. (i) The com-
bination of phenobarbital and acetaminophen increases
the risk of hepatotoxicity. (ii) The concurrent use of
phenobarbital and mirtazepine may inhibit mirtazepine
efficacy and therefore requires clinical monitoring. (iii)
Duloxetine increases the area under the plasma concen-
tration time curve (AUC) of metoprolol 1.8-fold. As a
result, blood pressure and heart rate monitoring are
required, particularly at the start and cessation of dulox-
etine therapy. Drugs that are used in Europe but not in
the U.S. explain a portion of the missing data.
Conclusions
The decision model reproducibly rates interactions and
identifies systematic differences. Ratings are based on
critical indicators of clinical significance, namely; the risk
of an SAE, the extent of medical intervention required,
the clinical surveillance required, the existence of a safer
alternative and the risk-benefit ratio. The decision model
is consistent with other rating systems, following re-
moval of systematic differences between methods. We
propose to supply the decision path alongside the inter-
action rating, to facilitate rating comprehensibility and
to assess mortality and morbidity rates in a clinical set-
ting. If factors such as length of hospital stay or risk of
complications are improved by using the model, then
the model represents a significant advance over existing
models.
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